Showing results (261-270 of 398) with videos related to

Sort By:
Pageof 40
Canadian Family Physician Medecin De Famille Canadien|September 18, 2007
Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?Richard H Hunt, Denis Choquette, Brian N Craig, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997
Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agentsM A Ihnat, J P Lariviere, A J Warren, et al.
Thrombosis Journal|June 7, 2019
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)Jan Beyer-Westendorf, A John Camm, Keith A A Fox, et al.
Circulation|May 20, 1998
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]D B Mark, P A Cowper, S D Berkowitz, et al.
BMJ (Clinical Research Ed.)|February 6, 1998
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort studyA Cogo, A W Lensing, M M Koopman, et al.
Archives of Pathology & Laboratory Medicine|April 17, 2004
Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX studyLouis Desjardins, Lucienne Bara, Florent Boutitie, et al.
JAMA|August 24, 2006
Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolismClive Kearon, Jeffrey S Ginsberg, Jim A Julian, et al.
The New England Journal of Medicine|February 17, 2012
Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancerGiancarlo Agnelli, Daniel J George, Ajay K Kakkar, et al.
Thrombosis and Haemostasis|October 3, 2013
Impact of age on the efficacy and safety of extended-duration thromboprophylaxis in medical patients. Subgroup analysis from the EXCLAIM randomised trialRoger D Yusen, Russell D Hull, Sebastian M Schellong, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|August 30, 2003
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX studyRaza Alikhan, Alexander T Cohen, Sophie Combe, et al.
Pageof 40